JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Journal of Nuclear Medicine Vol. 41 No. 12 1999-2010
© 2000 by Society of Nuclear Medicine
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Colnot, D. R.
Right arrow Articles by van Dongen, G. A.M.S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Colnot, D. R.
Right arrow Articles by van Dongen, G. A.M.S.

Phase I Therapy Study of 186Re-Labeled Chimeric Monoclonal Antibody U36 in Patients with Squamous Cell Carcinoma of the Head and Neck

David R. Colnot, Jasper J. Quak, Jan C. Roos, Arthur van Lingen, Abraham J. Wilhelm, Gerard J. van Kamp, Peter C. Huijgens, Gordon B. Snow and Guus A.M.S. van Dongen

Departments of Otolaryngology/Head and Neck Surgery, Nuclear Medicine, Clinical Chemistry, and Hematology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands


Figure 1
View larger version (58K):
[in this window]
[in a new window]

  		FIGURE 1. Whole-body scans of patient 4 acquired within 1 h after administration of 186Re-cMAb U36 and after 21, 72, and 144 h and 2 wk. Immediately after injection, most prominent activity is in blood pool. This activity remains high up to 72 h after injection. Relative uptake of radioimmunoconjugate in tumor in right oropharynx increases over time. Tumor becomes better delineated as background activity decreases.

 

Figure 2
View larger version (65K):
[in this window]
[in a new window]

  		FIGURE 2. Comparison of planar imaging of head and neck region of patient 1 21 h after administration of 99mTc-cMAb U36 (A) and 186Re-cMAb U36 (B). Accumulation of radiolabeled cMAb U36 is visible at tumor recurrence in right oropharynx.

 

Figure 3
View larger version (89K):
[in this window]
[in a new window]

  		FIGURE 3. CT scan (A) and planar anterior gamma camera scan (B) of patient 7 obtained 144 h after administration of 186Re-cMAb U36 show targeting of lung metastasis in upper lobe of left lung. Accumulation of 186Re-cMAb U36 is also visible on both sides of oropharynx, where recurrent tumor is present.

 

Figure 4
View larger version (12K):
[in this window]
[in a new window]

  		FIGURE 4. Relationship between AUC (expressed as %ID x h) determined for 0–25 h after injection for individual patients, both for 99mTc-cMAb U36 (horizontal axis) and for 186Re-cMAb U36 (vertical axis). Although relatively large variations are seen between patients, pharmacokinetic behavior of the 2 conjugates seems similar for individual patients (r = 0.94; P < 0.01).

 

Figure 5
View larger version (12K):
[in this window]
[in a new window]

  		FIGURE 5. Relationship between red marrow dose derived from whole-blood time–activity curve for 186Re-cMAb U36 and percentage decrease from baseline platelet count (r = 0.6; P < 0.05).

 

Figure 6
View larger version (108K):
[in this window]
[in a new window]

  		FIGURE 6. (A) CT scan of patient 13 shows large tumor originating from esophagus compressing stent that was placed for palliation 12 mo before RIT. (B) CT scan of same patient 3 wk after administration of 2.15 GBq 186Re-labeled cMAb U36. Sixty percent decrease in tumor size was observed as well as relaxation of stent.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2000 by the Society of Nuclear Medicine.